Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

JAK Inhibitors Competitive Landscape Report 2026: Comprehensive Insights on 40+ Companies and 45+ Drugs by Company, Product Type, Development Stage, Administration Route, Molecule Type

globenewswire.com
LLY The article mentions Eli Lilly and Company's JAK inhibitor OLUMIANT, approved for rheumatoid arthritis and atopic dermatitis, highlighting its role in the JAK inhibitors market without specific performance indicators. ABBV AbbVie is mentioned for its selective JAK inhibitor RINVOQ, used for rheumatoid arthritis and ulcerative colitis, indicating its presence in the JAK inhibitors market but without specific performance details. INCY Incyte is noted for its work in immunology and JAK-STAT pathway modulation, with a mention of Povorcitinib, positioning it within the JAK inhibitors sector without specific performance data.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "JAK Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.

The report delivers a detailed analysis of over 40 companies and 45+ drugs within the JAK inhibitors sector. The report encompasses therapeutics assessment by product type, development stage, administration route, and molecule type, while also addressing inactive pipeline products in this domain.

Geographical Coverage: Global

Janus kinase inhibitors (jakinibs) are effective in managing autoimmune and rheumatic diseases by blocking cytokine signaling through the JAK-STAT pathway. These inhibitors combat immune-mediated conditions, including rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD), with ongoing trials expanding potential applications to psoriasis arthritis (PsA) and various cancers. JAK inhibitors like tofacitinib and baricitinib block multiple JAKs, offering therapeutic benefits across a broad spectrum of autoimmune disorders, although they may pose risks of infection and hematological abnormalities.

Report Highlights:

JAK Inhibitors: Company and Product Profiles

Company Overview: Eli Lilly and Company

Lilly, a global healthcare leader, combines disease management and medical discoveries to foster healthier lives. With global operations, Lilly focuses on crafting life-altering medicines and enhancing disease understanding while maintaining community engagement through philanthropic efforts. OLUMIANT, a daily oral JAK inhibitor, is approved for rheumatoid arthritis and atopic dermatitis across multiple regions.

Company Overview: AbbVie

AbbVie emphasizes innovation and discovery in rheumatic diseases, aiming to meet patient needs via advanced scientific research. RINVOQ, their selective JAK inhibitor, showcases inhibitory potency for JAK-1, catering to rheumatoid arthritis, ulcerative colitis, and more.

JAK Inhibitors: Pipeline Therapies

Company Overview: Galapagos

Galapagos NV develops novel small molecules with diverse therapeutic potentials across numerous indications, with Filgotinib underlining its prowess.

Company Overview: Incyte

Incyte excels in immunology, focusing on dermatology and JAK-STAT pathway modulation to tackle inflammatory conditions with compounds like Povorcitinib.

Company Overview: MaxiNovel Pharmaceuticals

MaxiNovel, established in 2016, specializes in novel drug research, targeting cancer and autoimmune diseases. Their product MAX-40279 is under phase II trials for gastric and esophageal cancer.

JAK Inhibitors Analytical Perspective:

The report offers an extensive commercial assessment of the JAK inhibitors market, covering collaborations, agreements, licensing, and acquisitions.

Key Questions

Key Players

Key Products:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/m98meg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.